Lowering both should reduce the risk of cardiovascular events substantially.
METHODS: In a trial with 2-by-2 factorial design, we randomly assigned 12, participants at intermediate risk who did not have cardiovascular disease to rosuvastatin 10 mg per day or placebo and to candesartan 16 mg per day plus hydrochlorothiazide In the analyses reported here, we compared the participants assigned to combined therapy with rosuvastatin and the two hipertóniás jelentése agents with the participants assigned to dual placebo.
The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included heart failure, cardiac arrest, or revascularization.
The median follow-up was 5. The first coprimary outcome occurred in participants 3. The second coprimary outcome occurred in participants 4.
Muscle weakness and dizziness were more common in the combined-therapy group than in the dual-placebo group, but the overall rate of discontinuation of the trial regimen was similar in the two groups.